QuidelOrtho Corporation has announced a new partnership with BÜHLMANN Laboratories AG to introduce the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems. This collaboration aims to enhance gastrointestinal biomarker testing, specifically aiding in the diagnosis of inflammatory bowel disease $(IBD)$ and pancreatic insufficiency. The integration of these assays offers laboratories an efficient workflow, utilizing the CALEX Cap stool preparation device for optimized stool extraction. This partnership reflects a commitment to advancing diagnostics with non-invasive, patient-centric tools, ultimately improving patient care through fast and accurate test results.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quidelortho Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: LA23537) on July 14, 2025, and is solely responsible for the information contained therein.